OncoGenex reports preliminary data for OGX-427 in CRPC

OncoGenex Pharmaceuticals Inc. (NASDAQ:OGXI) said a greater proportion of patients receiving OGX-427 plus prednisone were progression free at 12 weeks, the primary endpoint, vs. prednisone alone in a Phase II trial to treat castration-resistant prostate cancer (71% vs. 33%). Additionally, 76% and 41% of patients receiving OGX-427 plus prednisone experienced an overall reduction and a greater than 50% reduction in prostate specific antigen (PSA) levels, respectively, vs. 53% and 20% for prednisone alone. The data were from 32 evaluable chemotherapy-naive patients in the open-label, North American trial, which is slated to enroll 72 patients. Data were presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium in San Francisco. ...